Effect of Adrenaline Concentration on Intraoperative Hemodynamics of Liposuction Patients

Effect of Adrenaline Concentration in Tumescence Solution on Intraoperative Hemodynamics of Liposuction Patients: A Randomized Controlled Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05822765

Enrollment

Registered

2023-04-21

Start date

2023-05-01

Completion date

2023-10-15

Last updated

2023-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraoperative Hemodynamics, Liposuction

Keywords

Adrenaline, Tumescence Solution

Brief summary

Liposuction is a procedure that has emerged over the last 30 years as a method to remove subcutaneous fat for cosmetic purposes. Numerous liposuction techniques have been developed .Tumescent liposuction involves using large volumes of dilute local anesthetic and epinephrine to facilitate anesthesia and decrease blood loss. Questions remain about the appropriate dose of local anesthetic, the use of general anesthesia in liposuction, and the setting in which the chosen liposuction method is used. Adrenaline is the most commonly used vasoconstrictor, the recommended concentration in the tumescent solution is 0.25-1 mg/L depending on the tissue vascularity. In the more vascular tissues, the concentration is 1 mg/L and is decreased to 0.5 mg/L in the less vascular areas of the body. The dose should not exceed 50μg/kg. If the maximum dose is anticipated to exceed, the procedure should be done in several stages.

Interventions

DRUGEpinephrine concentration of 1:1000000

Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter

DRUGEpinephrine concentration of 1:500000

Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

21 Years to 65 Years

Healthy volunteers

Inclusion criteria

* ASA I patients * scheduled for liposuction for abdomen and flanks and body contouring with liposuction

Exclusion criteria

* Bleeding disorders, anemia or hemoglobin level less than 11g/dl * Cardiovascular diseases, * Uncontrolled diabetes mellitus, * Collagen disorders, and * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Blood pressure	4 hours	Noninvasive Blood pressure will be recorded

Secondary

Measure	Time frame	Description
Heart rate	4 hours	Heart rate will be recorded every 10 minutes and results will be recorded

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026